
UK regulator rules benefits of lecanemab do not justify the cost
The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing… Read More















